Big Historical Income Statement
| PRM Stock | CAD 13.30 0.18 1.37% |
Historical analysis of Big Pharma income statement accounts such as Gross Profit of 296.2 K, Other Operating Expenses of 495.3 K, Total Operating Expenses of 414.7 K or Net Income Applicable To Common Shares of 5.1 M can show how well Big Pharma Split performed in making a profits. Evaluating Big Pharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Big Pharma's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Big Pharma Split latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Big Pharma Split is a good buy for the upcoming year.
Big |
About Big Income Statement Analysis
Big Pharma Split Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Big Pharma shareholders. The income statement also shows Big investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Big Pharma Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Big Pharma Split generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Big Pharma Split minus its cost of goods sold. It is profit before Big Pharma operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Big Pharma Split. It is also known as Big Pharma overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Big Pharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Big Pharma Split current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Big Pharma Split. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, Big Pharma's Depreciation And Amortization is very stable compared to the past year. As of the 1st of December 2024, Other Operating Expenses is likely to grow to about 495.3 K, while Selling General Administrative is likely to drop about 308.6 K.
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 5.4M | 3.7M | 311.8K | 296.2K | Total Revenue | 5.4M | 3.7M | 311.8K | 296.2K |
Big Pharma income statement Correlations
Click cells to compare fundamentals
Big Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Big Pharma income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | (1.8M) | (186.2K) | (4.6M) | (5.8M) | 363.2K | 381.4K | |
| Selling General Administrative | 287.1K | 216.2K | 370.6K | 357.8K | 334.6K | 308.6K | |
| Total Revenue | 2.4M | 589.3K | 5.4M | 3.7M | 311.8K | 296.2K | |
| Gross Profit | 2.2M | 589.3K | 5.4M | 3.7M | 311.8K | 296.2K | |
| Other Operating Expenses | 634.7K | 323.8K | 505.7K | 565.1K | 311.8K | 495.3K | |
| Operating Income | 454.7K | 265.4K | 4.9M | 3.1M | (139.7K) | (132.7K) | |
| Net Income From Continuing Ops | 3.1M | 265.4K | 4.9M | 3.1M | (139.7K) | (132.7K) | |
| Ebit | 454.7K | 265.4K | 4.9M | 3.1M | (502.9K) | (477.8K) | |
| Ebitda | 454.7K | 265.4K | 4.9M | 3.1M | (139.7K) | (132.7K) | |
| Total Operating Expenses | 396.5K | 323.8K | 505.7K | 565.1K | 311.8K | 414.7K | |
| Income Before Tax | 3.1M | 265.4K | 4.9M | 3.1M | (645.4K) | (613.1K) | |
| Total Other Income Expense Net | 2.7M | (403.6K) | (396.3K) | (3.4M) | (505.7K) | (531.0K) | |
| Net Income Applicable To Common Shares | 2.1M | 2.6M | (217.4K) | 4.2M | 4.8M | 5.1M | |
| Net Income | 5.8M | 265.4K | 4.9M | 3.1M | (139.7K) | (132.7K) | |
| Income Tax Expense | (2.7M) | (217.4K) | 4.2M | 2.4M | (505.7K) | (480.4K) | |
| Cost Of Revenue | 238.2K | 277.3K | 356.0K | 419.5K | 308.6K | 343.6K |
Pair Trading with Big Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Big Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Big Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Big Stock
Moving against Big Stock
The ability to find closely correlated positions to Big Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Big Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Big Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Big Pharma Split to buy it.
The correlation of Big Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Big Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Big Pharma Split moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Big Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Big Stock
Big Pharma Split Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Big Pharma shareholders. The income statement also shows Big investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).